New data shows that cabozantinib, a drug already approved in the treatment of clear cell renal cell carcinoma (ccRCC), elicited promising results in patients with less common non-clear…
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts presented results from the KEYNOTE-427 study at the Genitourinary Cancers…
A phase 1b study showed pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) in patients with previously untreated mRCC. “The risk of death was…
With the growth of immunotherapies in recent years as an effective melanoma treatment option, there are still patients who do not respond well to immunotherapies. Hildur Helgadottir, MD,…
Interim results from the preliminary analysis of the JAVELIN-Renal 101 trial suggest that adding immunotherapy to a targeted agent appears to significantly improve progression-free survival (PFS) when compared with a…